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Table 1
Effect of Statin on Immunomes
Statin vs.
non-statin
D30 (%)
P-value Median(Range)
Non-statin
exposed
Median(Range)
Statin exposed
Absolute
Lymphocyte
count
0.04688 850 (100-1300) 774.8 (109-2120)
DR+/14+ (absolute) 0.375 77.6 (43.1-86.3) 69.3 (19.2-92.1)
DR-/14+ (absolute) 0.1094 12.5 (2.7-34.4) 25.4 (1.8-78.6)
CD3+/56-/16- 0.04688 55 (15.4-78.2) 78.7 (52.5-95.8)
CD19+ 1 1 (0.2-2.0) 0.7 (0-39.4)
CD69 +/CD3+ 0.8655 3.2 (0.7-4.7) 2.7 (1.1-4.4)
CD3+/DR+ 1 5 (1.4-30.1) 5.1 (0.4-13.7)
CD3+/DR - 0.1563 48 (17.5-77.1) 70.1 (52.9-85.1)
CD3-/56+/16+ 0.03125 33.5 (16.5-42.2) 7.9 (2.7-21.0)
CD3-/56+/16+/314+ 0.03125 18.1 (6.5-34.0) 4.6 (0.7-10)
CD3-/56+/16+/117- 0.03125 22.4 (11.8-36.4) 6.3 (0.9-12.9)
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congenital immunosuppression.
Figure 1. TCR Repertoire Size: NRM v. other patients
The ﬁgure shows a comparison of TCR repertoire size, estimated based on
high-throughput sequencing of TCRb rearrangements, for all surviving
patients (N is indicated below each panel) with and without eventual non-
relapse mortality (NRM). TCR repertoire size values are given as quartiles for
both populations, with whiskers representing the maximum and minimum
values. Signiﬁcance is assessed using a one-tailed Mann-Whitney U test;
patients who went on to suffer from non-relapse mortality had signiﬁcantly
lower estimated repertoire sizes at 56 and 100 days post-transplant.
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Introduction: Acute graft-versus-host-disease (aGVHD) is
a frequent and lethal complication of HSCT despite current
prophylaxis. Release of pro-inﬂammatory cytokines lead to
damage of host tissues. Statins have been shown to reduce
pro-inﬂammatory cytokines while increasing the migration
of anti-inﬂammatory cytokines, especially when donor and
recipient are exposed to it, thus reducing aGVHD. We
present data on 14 patients enrolled in an ongoing phase II
study evaluating the efﬁcacy of atorvastatin as aGVHD
prophylaxis in patients undergoing matched-related donor
AHSCT.Method: In this phase II study donors receive atorvastatin 40
mg daily for at least 14 days before leukapheresis. Recipient
patients receive Atorvastatin 40mg daily starting at least 7
days before initiation of transplant conditioning regimen in
addition to standard approved GVHD prophylaxis with
tacrolimus and methotrexate. Atorvastatin is continued until
development of grade II or higher aGVHD, cessation of
aGVHD prophylaxis and or adverse event. We compared the
immune reconstitution pattern of patients on statin to those
of historic control patients not on statin matched to age, sex,
type of AHSCT and intensity of regimen.
Result: Median age of patients is 47 (range 27-67) and of
donor 46.5 (29-64). Ten patients received reduced intensity
AHSCT. Median neutrophil and platelets engraftment were
18.9 and 12.9 days. With a median follow up of 120 days (23-
287), two patients have relapsed one of whom died due to
disease. The median day 30 CD3 and CD34 chimerism were
81% and 100%. Two patients (14%) have developed grade II
aGVHD with no patients developing grade III or IV aGVHD.
Two patients developed chronic GVHD both mild and
limited. At day 30 post HSCT, compared to historic control,
patients exposed to statin had no difference in B cells(CD19+)
or total T cells (CD3+/DR+; CD3+/DR-), but a signiﬁcant
decline in NK cells, including total NK cells and NK cells
positive for CD314 (Table 1).
Conclusion: While this is a small sample, and no conclusion
can be deduced, it is interesting to note the signiﬁcant
difference in the number of NK cells in patients exposed to
statin as compared to historic control.179
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after hematopoeitc cell transplantation (HCT) is critical for
the control of post-transplant infections, establishment of
graft tolerance and, in some cases, mediation of graft-versus
leukemia effects. Natural Killer (NK) cells, being the ﬁrst in
line of defense against tumors and infections, are also the
earliest among lymphocyte populations to reconstitute and
achieve functional maturity after transplantation. However,
many HCT recipients with normal recovery of NK cells
continue to suffer from complications including infections
and disease relapse suggesting that different NK cell subsets
may be responsible for anti-leukemic or anti-viral immune
response. Here, we set out to determine in healthy individ-
uals, whether different NK cell subsets (cytolytic or regula-
tory) elicit unique immune responses against different
targets (leukemia cells or herpes viruses).
Methods: Peripheral Blood Mononuclear Cells (PBMNCs)
from 25 healthy donors were stimulated with different
targets including a leukemic cell line (K562) and herpesviral
(Epstein - Barr virus, EBV) infected cell lysate. A 5-colour ﬂow
cytometry based estimation of cytotoxicity (expression of
CD107a, a surrogate marker for degranulation) and cytokine
(IFN-g) production was performed for both CD56brightCD16-
neg regulatory and CD56dimCD16pos cytolytic NK cell subsets.
Results: Different NK cell subsets were immunodominant
against different targets. Leukemia (K562) e speciﬁc response
includes both degranuation and IFN-g productionmediated by
the cytolytic and regulatory NK cell subsets. On the contrary,
EBV speciﬁc NK cell response was primarily characterized by
degranulation and was dominated by cytolytic NK cells. A
consistent shedding of CD16 was found associated with
degranulationof cytolyticNKcells in response to EBVbut not to
K562cells. CytolyticNKcells in general exhibited abifunctional
immune response against both targets while regulatory NK
cells were primarily IFN-g producers.
Conclusions: NK cell subsets elicit a unique immune
response against different targets (leukemia cells or
herpesviruses). Assessment of posttransplant recovery of
these target speciﬁc functional NK cell subsets will be more
relevant for the prediction of transplant outcomes and may
have future implications for the cellular therapy/prophylaxis
of herpesviral disease or leukemia relapse.180
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Allogeneic hematopoietic stem cell transplantation
(SCT) is the best treatment for numerous types of hema-
tological malignancies. However, graft-versus-host disease
(GVHD) is the major cause of morbidity and mortality and
its effect on T cell regeneration greatly exacerbates the
immunodeﬁciency normally associated with this treatment.
As a result, patients with GVHD are profoundly lympho-
penic and T cell reconstitution typically takes several
months or years.
We previously reported that IL7Ra-/- mice have a peri-
pheral lymphoid niche that is highly permissive for homeo-
static proliferation (HP) of CD4+ T cells. Given that CD4+ T
cells regeneration is impaired during GVHD, we hypothe-
sized that using IL7Ra-/- bone marrow (BM) might improve
their recovery in GVHD hosts. To study the impact of GVHD
on the peripheral niche regulating CD4 HP, we used themouse model B6 into B6D2F1. Since IL7Ra-/- DCs support
efﬁciently HP of naïve CD4+ T cells during lymphopenia, we
used BM stem cells from B6IL7Ra-/- mice and induced GVHD
by adding 1x106 B6 T cells. Finally, to understand the impact
of GVHD on HP, we transferred CFSE labelled anti-HY CD4+ T
cells (Marilyn) into GVHD hosts and measured their
homeostatic proliferation 7 days later.
In non GVHD hosts, Marilyn T cells underwent robust HP
while they completely failed in GVHD hosts. Absence of HP
during GVHD was associated with a severe depletion of all
DC subsets, including myeloid, lymphoid and pDCs. Low
number of DCs during GVHD was in part due to their elimi-
nation by GVHD T cells but most importantly to a myelo-
suppression affecting DC production from BM progenitor
cells. Interestingly, treatment of GVHDmice with FLT3 ligand
(FL) signiﬁcantly increased the number of DCs, yet it was
insufﬁcient for restoring CD4 HP. Given that stromal cells and
IL7 mRNA levels were also diminished in GVHD hosts, we
provided both FL and IL-7 to GVHD mice and signiﬁcantly
restored HP of Marilyn CD4+ T cells in this setting.
Thus far, our data support a model wherein loss of CD4 HP
during GVHD relates to lower numbers of DC and diminished
systemic IL7.181
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Background: Enhanced immune responses post autologous
HCT is known to be beneﬁcial for long term disease control in
MM. Early responses are mediated by NK cells and alternate
inhibitory/stimulatory pathways that include the cos-
timulatory molecules. This pilot study assesses the expres-
sion of NK cytolytic receptor (CD16) as well as the
stimulatory (OX-40, ICOS, 4-1BB, CD28, NKG2D) and inhibi-
tory (PD-1 and CTLA-4) molecules on NK cells after auto-HCT
in MM patients.
Methods: 22 patients with MM undergoing HCT, median age
59.6 years (36 - 71.4), were included in the study. Peripheral
blood sampleswere taken3daysprior toHCTand14,30, 60, 90,
180 days after HCT. At d180 post-HCT, 18/22 patients were
receiving lenalidomidewith d86 as median start date. NK cells
and their costimulatory molecules were evaluated by ﬂowcy-
tometry using 2 six color panels of antibodies. OnewayANOVA
